A topical cyclooxygenase (COX) inhibitor formulation comprising an inhibitor of COX-1 and/or COX-2, one or more long chain monounsaturated fatty acids, long chain monounsaturated fatty alcohols, terpenes, or combinations thereof; and a solvent mixture comprising ethanol, propylene glycol, 2-(2-Ethoxyethoxy)ethanol, and optionally dimethylsulfoxide.

This invention relates to methods of treating and/or preventing cardiovascular diseases and conditions and to methods of reducing the risk of cardiovascular death, reducing the risk of hospitalization for heart failure, reducing the risk of hospitalization for heart failure, reducing the risk of urgent visits for heart failure, and slowing the progression of kidney disease.

This invention relates to methods of treating and/or preventing cardiovascular diseases and conditions and to methods of reducing the risk of cardiovascular death, reducing the risk of hospitalization for heart failure, reducing the risk of hospitalization for heart failure, reducing the risk of urgent visits for heart failure, and slowing the progression of kidney disease.

A method is provided for lowering blood sugar in a subject in need thereof by administering a gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes empagliflozin, canagliflozin, and ertugliflozin. In some embodiments, the gliflozin Sodium-Glucose Cotransport 2 inhibitor pharmaceutical composition includes (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol or a pharmaceutically acceptable salt thereof.

A composition with efficacies of improving chronic wound healing, particularly diabetic wound healing, mainly selected from the group consisting of combinations of at least two of the following three components: (1) an anti-inflammatory agent selected from the group consisting of acteoside, isoacteoside and a combination thereof, (2) an astringent selected from the group consisting of gallic acid, subgallic acid, their salts and a combination thereof, and (3) a cooling agent selected from the group consisting of borneal, menthol and a combination thereof, and optionally combined with one or more pharmaceutically acceptable carriers. The present invention also provides use of said composition in the preparation of a medicament for treating a chronic wound, particularly a diabetic wound.

A composition with efficacies of improving chronic wound healing, particularly diabetic wound healing, mainly selected from the group consisting of combinations of at least two of the following three components: (1) an anti-inflammatory agent selected from the group consisting of acteoside, isoacteoside and a combination thereof, (2) an astringent selected from the group consisting of gallic acid, subgallic acid, their salts and a combination thereof, and (3) a cooling agent selected from the group consisting of borneal, menthol and a combination thereof, and optionally combined with one or more pharmaceutically acceptable carriers. The present invention also provides use of said composition in the preparation of a medicament for treating a chronic wound, particularly a diabetic wound.

An antimicrobial composition includes an aqueous and/or ethanolic solution of iodine and hydrogen peroxide, which is acidified. The acidifying agent may be aspirin, hydrochloric acid, or other acidic agent tolerable to the body. The composition may also include a witch hazel extract, or alternately hamamelitannin, gallic acid, or other components thereof that effect quorum signaling inhibition that blocks and erodes microbe-induced biofilm on cellular and device surfaces. Acetohydroxamic acid may be combined with the composition as a counter to microbe-induced alkalinization, particularly in urine. Moreover, a metal, halogen, and combinations of these, such as a silver colloid, may be added as a secondary microbicidal agent. The antimicrobial composition may be applied topically to or instilled through an indwelling urinary catheter or applied as a device surface-coating on other medical devices.

An antimicrobial composition includes an aqueous and/or ethanolic solution of iodine and hydrogen peroxide, which is acidified. The acidifying agent may be aspirin, hydrochloric acid, or other acidic agent tolerable to the body. The composition may also include a witch hazel extract, or alternately hamamelitannin, gallic acid, or other components thereof that effect quorum signaling inhibition that blocks and erodes microbe-induced biofilm on cellular and device surfaces. Acetohydroxamic acid may be combined with the composition as a counter to microbe-induced alkalinization, particularly in urine. Moreover, a metal, halogen, and combinations of these, such as a silver colloid, may be added as a secondary microbicidal agent. The antimicrobial composition may be applied topically to or instilled through an indwelling urinary catheter or applied as a device surface-coating on other medical devices.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.

The present invention identifies AKR1C1 as the first lipedema-associated gene. The invention provides methods for diagnosing or assessing an individual's susceptibility to lipedema by the analysis of the AKR1C1 gene or the expression levels of its product and related metabolites. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lipedema.